Efficacy and safety of antiplatelet therapy in patients with acute ischemic stroke complicated with gastric cancer
10.3969/j.issn.1673-9701.2024.03.001
- VernacularTitle:合并胃癌的急性缺血性脑卒中患者的抗血小板治疗有效性及安全性研究
- Author:
Shuiqing LYU
1
,
2
;
Debin ZHU
2
,
3
;
Linhua YAO
2
,
3
;
Jingjing MIN
1
,
2
Author Information
1. Department of Neurology, the First People&rsquo
2. s Hospital of Huzhou, Huzhou 313000, Zhejiang, China
3. Department of Gastroenterology, the First People&rsquo
- Publication Type:Journal Article
- Keywords:
Acute ischemic stroke;
Gastric cancer;
Safety;
Efficacy
- From:
China Modern Doctor
2024;62(3):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of antiplatelet therapy in patients with acute ischemic stroke(AIS)complicated with gastric cancer.Methods Clinical data of 89 patients with AIS complicated with gastric cancer who were hospitalized in the First People's Hospital of Huzhou from January 2018 to October 2022 were retrospectively analyzed.The patients were divided into treatment group(59 cases)and untreated group(30 cases)according to whether they received antiplatelet therapy or not,and the clinical characteristics and prognosis of the two groups were compared.To analyze the clinical features and influencing factors of gastrointestinal bleeding complicated by antiplatelet therapy in AIS patients with gastric cancer.Results The patients in treatment group were younger than those in untreated group,and had more history of antiplatelet therapy,hypertension and cardiovascular disease,the difference was statistically significant(P<0.05).The National Institute of Health stroke scale(NHISS)and modified Rankin scale(mRs)of patients in treatment group were lower than those in untreated group after antiplatelet therapy,the difference was statistically significant(P<0.05).The incidence of bleeding in treated group was significantly higher than that in untreated group(P<0.05),most of the patients had mild hemoglobin decline.Multivariate Logistic analysis suggested that chronic renal insufficiency,gastric cancer lesion diameter≥2cm and T1-T2 stage are risk factors for gastrointestinal bleeding in AIS patients with gastric cancer after taking aspirin for antiplatelet therapy.Conclusion In AIS patients with gastric cancer,aspirin antiplatelet therapy can effectively improve cerebrovascular function and reduce the degree of brain nerve damage.However,when these patients are combined with T1-T2 stage,chronic renal insufficiency and gastric cancer lesion diameter≥2cm,gastrointestinal bleeding is easy to occur.
